Food and Drug Administration/National Institutes of Health/National Science Foundation Public Workshop on Computer Methods for Medical Devices, 20666-20667 [2013-07923]

Download as PDF 20666 Federal Register / Vol. 78, No. 66 / Friday, April 5, 2013 / Notices Specifically, the consortia will facilitate the development, production, and distribution of pediatric medical devices by: (1) Encouraging innovation and connecting qualified individuals with pediatric device ideas with potential manufacturers; (2) mentoring and managing pediatric device projects through the development process, including product identification, prototype design, device development, and marketing; (3) connecting innovators and physicians to existing Federal and non-Federal resources; (4) assessing the scientific and medical merit of proposed pediatric device projects; and (5) providing assistance and advice as needed on business development, personnel training, prototype development, and postmarketing needs. C. Eligibility Information The grants are available to any domestic, public or private, nonprofit entity (including State and local units of government). Federal agencies that are not part of HHS may apply. Agencies that are part of HHS may not apply. Organizations that engage in lobbying activities, as described in section 501(c)(4) of the Internal Revenue Code of 1968, are not eligible to receive grant awards. DiseasesConditions/default.htm. (FDA has verified the Web site addresses throughout this document, but FDA is not responsible for any subsequent changes to the Web sites after this document publishes in the Federal Register.) Persons interested in applying for a grant may obtain an application at https://grants.nih.gov/grants/forms.htm. For all paper application submissions, the following steps are required: • Step 1: Obtain a Dun and Bradstreet (DUNS) Number. • Step 2: Register With System for Award Management. Steps 1 and 2, in detail, can be found at https://www07.grants.gov/applicants/ organization_registration.jsp. After you have followed these steps, submit paper applications to: Vieda Hubbard, Grants Management Specialist, Office of Acquisitions & Grant Services, 5630 Fishers Lane, Rm. 2034, Rockville, MD 20857, phone: 301–827–7177. Dated: April 2, 2013. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2013–07948 Filed 4–4–13; 8:45 am] BILLING CODE 4160–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES II. Award Information/Funds Available Food and Drug Administration A. Award Amount The estimated amount of funds available for support of four to five consortia awarded as a result of this announcement is $3 million for fiscal year 2013. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. Although PDC financial plans include support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications. [Docket No. FDA–2013–N–0345] mstockstill on DSK4VPTVN1PROD with NOTICES B. Length of Support Grants will be awarded on a competitive basis up to $750,000 in total (direct plus indirect) costs per year for up to 5 years, contingent upon favorable annual review and an additional midcycle review after 21⁄2 years of funding. III. Paper Application, Registration, and Submission Information To submit a paper application in response to this FOA, applicants should first review the full announcement located at https://grants.nih.gov/grants/ guide/ or https://www.fda.gov/For Industry/DevelopingProductsforRare VerDate Mar<15>2010 17:14 Apr 04, 2013 Jkt 229001 Food and Drug Administration/National Institutes of Health/National Science Foundation Public Workshop on Computer Methods for Medical Devices AGENCY: Food and Drug Administration, HHS. Notice of public workshop; request for comments. ACTION: The Food and Drug Administration (FDA) is announcing its fifth public workshop on Computer Methods for Medical Devices entitled ‘‘FDA/NIH/NSF Workshop on Computer Models and Validation for Medical Devices.’’ The purpose of the workshop is to present, discuss, and receive input on an FDA library of models and data relevant to medical devices (day 1) and present, discuss, and receive input on a strategy to assess the credibility of computer models used to evaluate medical devices (day 2). DATES: Dates and Times: The workshop will be held on June 11 and 12, 2013, from 8:30 a.m. to 5:30 p.m. Location: The public workshop will be held at FDA’s White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 SUMMARY: PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993–0002. Entrance for the public meeting participants (non-FDA employees) is through Building 1 where routine security check procedures will be performed. For parking and security information, please refer to: https:// www.fda.gov/AboutFDA/ WorkingatFDA/BuildingsandFacilities/ WhiteOakCampusInformation/ ucm241740.htm. Contact Persons: Donna Lochner, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 62, Rm. 3220, Silver Spring, MD 20993, 301–796–6309, Donna.Lochner@fda.hhs.gov; or Tina M. Morrison, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 1272, Silver Spring, MD 20993, 301–796–6310, Tina.Morrison@fda.hhs.gov. Registration: Registration is free and will be on a first-come, first-served basis. Persons interested in attending this public workshop must register online by 4 p.m. on May 31, 2013. Early registration is recommended because facilities are limited and, therefore, FDA may limit the number of participants from each organization. If time and space permit, onsite registration on the day of the public workshop will be provided beginning at 8 a.m. To register for the public workshop, please visit FDA’s Medical Devices News & Events—Workshops & Conferences calendar at https:// www.fda.gov/MedicalDevices/ NewsEvents/WorkshopsConferences/ default.htm. Select this public workshop from the posted events list. Please provide complete contact information for each attendee, including name, title, affiliation, mailing address, email address, and telephone number. Those without Internet access should contact Susan Monahan to register (301– 796–5661 or Susan.Monahan@fda.hhs.gov). Registrants will receive confirmation after they have been accepted. You will be notified if you are on a waiting list. If you need special accommodations due to a disability, please contact Susan Monahan (Susan.Monahan@fda.hhs.gov or 301–796–5661) no later than May 28, 2013. Streaming Webcast of the Public Workshop: This workshop will also be available via Webcast. Persons interested in viewing the Webcast must register online by 4 p.m. on May 31, 2013. Early registration is recommended because Webcast connections are limited. Organizations are requested to E:\FR\FM\05APN1.SGM 05APN1 Federal Register / Vol. 78, No. 66 / Friday, April 5, 2013 / Notices register all participants, but to view using one connection per location. Webcast participants will be sent technical system requirements after registration and connection access information after June 4, 2013. If you have never attended a Connect Pro event before, test your connection at https://collaboration.fda.gov/common/ help/en/support/meeting_test.htm. To get a quick overview of the Connect Pro program, visit https://www.adobe.com/ go/connectpro_overview. (FDA has verified the Web site addresses in this document, but FDA is not responsible for any subsequent changes to the Web sites after this document publishes in the Federal Register.) Comments: FDA is holding this public workshop to obtain information on the topics identified in Section II of this document. In order to permit the widest possible opportunity to obtain public comment, FDA is soliciting either electronic or written comments on all aspects of the public workshop topics. The deadline for submitting comments related to this public workshop is July 10, 2013. Regardless of attendance at the public workshop, interested persons may submit either electronic comments to https://www.regulations.gov or written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. It is only necessary to send one set of comments. Please identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at https:// www.regulations.gov. SUPPLEMENTARY INFORMATION: mstockstill on DSK4VPTVN1PROD with NOTICES I. Background The Center for Devices and Radiological Health (CDRH) believes that computer modeling and simulation (M&S) has the potential to substantially augment traditional models used to evaluate medical devices; i.e., animal, bench, and human models, and to accelerate and streamline the total product life cycle of a medical device. The use of computer models to simulate multiple use conditions and to visualize and display complex processes and data can revolutionize the way medical outcomes and medical devices are understood. Nonproprietary computer models could benchmark device performance, yet lack of access to biomedical data to construct the models and rigorous methods to validate the VerDate Mar<15>2010 17:14 Apr 04, 2013 Jkt 229001 models limit their credibility and use. Before substantial advances in the use of M&S for regulatory decision making can be attained, a strategy and consistent framework to assess the credibility of M&S is needed. Moreover, to foster good science for M&S in the medical device community, CDRH needs to leverage the expertise in industry and academia to develop a strategy to scientifically assess the credibility of M&S and to develop a resource to publicize biomedical data, models and their validation for regulatory use. II. Topics Historically, M&S have been used as development and design optimization tools, rather than methods by which performance of final devices can be demonstrated. Further, modeling studies that are submitted to the Agency are supplemental and complement animal, bench and human testing provided in: • Investigational Device Exemptions (investigational devices), • 510(k) notifications (class II devices), and • Pre-Market Approval applications (class III devices). Some of the challenges with the current uses of M&S are: • Reports typically lack sufficient details for adequate assessment because there are no reporting standards for computational modeling, • Lack of sensitivity and uncertainty analyses for crucial input parameters, such as geometry, physical properties, boundary conditions, • Lack of adequate validation to support the use of the computational model, and • Lack of complete understanding of physiological loads and variations in patient populations. Adequate verification and validation (V&V) are necessary in order to foster confidence and wider acceptance of M&S for use in medical device evaluation. Therefore, CDRH, in collaboration with the American Society of Mechanical Engineers, has been drafting a guide on the ‘‘Verification and Validation of Computational Modeling for Medical Devices.’’ The strategy is meant to create a framework for determining the risk associated with using a computational model in a specific context of use (COU) to inform decision making and for determining ‘‘how much’’ V&V is necessary to support the model for its COU. The two main components of this strategy are the Risk Assessment Matrix and the Credibility Assessment Matrix. Both of these tools will be presented and PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 20667 discussed at the workshop. Note that these tools are still in DRAFT format. The workshop will also describe and discuss FDA’s efforts to create a resource or Library of biomedical data and models that can be used in regulatory applications. Key features and questions related to development of the Library and curation of data and models for the Library will be discussed. The goal of the FDA/NIH/ NSF Workshop on Computer Modeling and Validation for Medical Devices is to discuss and receive input on these tools to enhance their utility in the community. Dated: April 1, 2013. Peter Lurie, Acting Associate Commissioner for Policy and Planning. [FR Doc. 2013–07923 Filed 4–4–13; 8:45 am] BILLING CODE 4160–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301–496–7057; fax: 301–402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. SUMMARY: Highly Potent and Selective Deubiquitinating Enzyme Inhibitor Description of Technology: Available for licensing are inhibitors that target the USP1/UAF1 deubiquitnating enzyme (DUB) complex. The FDA approval and commercial success of E:\FR\FM\05APN1.SGM 05APN1

Agencies

[Federal Register Volume 78, Number 66 (Friday, April 5, 2013)]
[Notices]
[Pages 20666-20667]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-07923]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-N-0345]


Food and Drug Administration/National Institutes of Health/
National Science Foundation Public Workshop on Computer Methods for 
Medical Devices

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing its fifth 
public workshop on Computer Methods for Medical Devices entitled ``FDA/
NIH/NSF Workshop on Computer Models and Validation for Medical 
Devices.'' The purpose of the workshop is to present, discuss, and 
receive input on an FDA library of models and data relevant to medical 
devices (day 1) and present, discuss, and receive input on a strategy 
to assess the credibility of computer models used to evaluate medical 
devices (day 2).

DATES: Dates and Times: The workshop will be held on June 11 and 12, 
2013, from 8:30 a.m. to 5:30 p.m.
    Location: The public workshop will be held at FDA's White Oak 
Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great 
Room (Rm. 1503), Silver Spring, MD 20993-0002. Entrance for the public 
meeting participants (non-FDA employees) is through Building 1 where 
routine security check procedures will be performed. For parking and 
security information, please refer to: https://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.
    Contact Persons: Donna Lochner, Center for Devices and Radiological 
Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 
62, Rm. 3220, Silver Spring, MD 20993, 301-796-6309, 
Donna.Lochner@fda.hhs.gov; or Tina M. Morrison, Center for Devices and 
Radiological Health, Food and Drug Administration, 10903 New Hampshire 
Ave., Bldg. 66, Rm. 1272, Silver Spring, MD 20993, 301-796-6310, 
Tina.Morrison@fda.hhs.gov.
    Registration: Registration is free and will be on a first-come, 
first-served basis. Persons interested in attending this public 
workshop must register online by 4 p.m. on May 31, 2013. Early 
registration is recommended because facilities are limited and, 
therefore, FDA may limit the number of participants from each 
organization. If time and space permit, onsite registration on the day 
of the public workshop will be provided beginning at 8 a.m.
    To register for the public workshop, please visit FDA's Medical 
Devices News & Events--Workshops & Conferences calendar at https://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm. 
Select this public workshop from the posted events list. Please provide 
complete contact information for each attendee, including name, title, 
affiliation, mailing address, email address, and telephone number. 
Those without Internet access should contact Susan Monahan to register 
(301-796-5661 or Susan.Monahan@fda.hhs.gov). Registrants will receive 
confirmation after they have been accepted. You will be notified if you 
are on a waiting list.
    If you need special accommodations due to a disability, please 
contact Susan Monahan (Susan.Monahan@fda.hhs.gov or 301-796-5661) no 
later than May 28, 2013.
    Streaming Webcast of the Public Workshop: This workshop will also 
be available via Webcast. Persons interested in viewing the Webcast 
must register online by 4 p.m. on May 31, 2013. Early registration is 
recommended because Webcast connections are limited. Organizations are 
requested to

[[Page 20667]]

register all participants, but to view using one connection per 
location. Webcast participants will be sent technical system 
requirements after registration and connection access information after 
June 4, 2013. If you have never attended a Connect Pro event before, 
test your connection at https://collaboration.fda.gov/common/help/en/support/meeting_test.htm. To get a quick overview of the Connect Pro 
program, visit https://www.adobe.com/go/connectpro_overview. (FDA has 
verified the Web site addresses in this document, but FDA is not 
responsible for any subsequent changes to the Web sites after this 
document publishes in the Federal Register.)
    Comments: FDA is holding this public workshop to obtain information 
on the topics identified in Section II of this document. In order to 
permit the widest possible opportunity to obtain public comment, FDA is 
soliciting either electronic or written comments on all aspects of the 
public workshop topics. The deadline for submitting comments related to 
this public workshop is July 10, 2013.
    Regardless of attendance at the public workshop, interested persons 
may submit either electronic comments to https://www.regulations.gov or 
written comments to the Division of Dockets Management (HFA-305), Food 
and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 
20852. It is only necessary to send one set of comments. Please 
identify comments with the docket number found in brackets in the 
heading of this document. Received comments may be seen in the Division 
of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, 
and will be posted to the docket at https://www.regulations.gov.

SUPPLEMENTARY INFORMATION:

I. Background

    The Center for Devices and Radiological Health (CDRH) believes that 
computer modeling and simulation (M&S) has the potential to 
substantially augment traditional models used to evaluate medical 
devices; i.e., animal, bench, and human models, and to accelerate and 
streamline the total product life cycle of a medical device. The use of 
computer models to simulate multiple use conditions and to visualize 
and display complex processes and data can revolutionize the way 
medical outcomes and medical devices are understood. Nonproprietary 
computer models could benchmark device performance, yet lack of access 
to biomedical data to construct the models and rigorous methods to 
validate the models limit their credibility and use. Before substantial 
advances in the use of M&S for regulatory decision making can be 
attained, a strategy and consistent framework to assess the credibility 
of M&S is needed. Moreover, to foster good science for M&S in the 
medical device community, CDRH needs to leverage the expertise in 
industry and academia to develop a strategy to scientifically assess 
the credibility of M&S and to develop a resource to publicize 
biomedical data, models and their validation for regulatory use.

II. Topics

    Historically, M&S have been used as development and design 
optimization tools, rather than methods by which performance of final 
devices can be demonstrated. Further, modeling studies that are 
submitted to the Agency are supplemental and complement animal, bench 
and human testing provided in:
     Investigational Device Exemptions (investigational 
devices),
     510(k) notifications (class II devices), and
     Pre-Market Approval applications (class III devices).

Some of the challenges with the current uses of M&S are:
     Reports typically lack sufficient details for adequate 
assessment because there are no reporting standards for computational 
modeling,
     Lack of sensitivity and uncertainty analyses for crucial 
input parameters, such as geometry, physical properties, boundary 
conditions,
     Lack of adequate validation to support the use of the 
computational model, and
     Lack of complete understanding of physiological loads and 
variations in patient populations.
    Adequate verification and validation (V&V) are necessary in order 
to foster confidence and wider acceptance of M&S for use in medical 
device evaluation. Therefore, CDRH, in collaboration with the American 
Society of Mechanical Engineers, has been drafting a guide on the 
``Verification and Validation of Computational Modeling for Medical 
Devices.'' The strategy is meant to create a framework for determining 
the risk associated with using a computational model in a specific 
context of use (COU) to inform decision making and for determining 
``how much'' V&V is necessary to support the model for its COU. The two 
main components of this strategy are the Risk Assessment Matrix and the 
Credibility Assessment Matrix. Both of these tools will be presented 
and discussed at the workshop. Note that these tools are still in DRAFT 
format.
    The workshop will also describe and discuss FDA's efforts to create 
a resource or Library of biomedical data and models that can be used in 
regulatory applications. Key features and questions related to 
development of the Library and curation of data and models for the 
Library will be discussed. The goal of the FDA/NIH/NSF Workshop on 
Computer Modeling and Validation for Medical Devices is to discuss and 
receive input on these tools to enhance their utility in the community.

    Dated: April 1, 2013.
Peter Lurie,
Acting Associate Commissioner for Policy and Planning.
[FR Doc. 2013-07923 Filed 4-4-13; 8:45 am]
BILLING CODE 4160-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.